Figure Legend
The essential role of DNA methylation in X chromosome inactivation and imprinting is widely recognized, but we know little about tissue-specific DNA methylation or DNA methylation changes in regulatory regions. Several international epigenome projects, including the Human Epigenome Project, plan to generate detailed maps of DNA methylation in normal cells and cells that are altered during disease pathogenesis. The SnapShot shows a summary of our current knowledge of the DNA methylation patterns in normal human cells and in human cells in different disease states. In normal cells, DNA methylation is restricted to a few tissue-specific genes (white arrow heads) and imprinted genes (gray arrow heads) and throughout the inactive X (X 1 ) chromosome (juxtaposed blue lines) in females. DNA methylation changes in disease are indicated by red (hypermethylation) or green (hypomethylation) bars inside the chromosome; methylation in normal cells is indicated by blue bars inside chromosomes. Only representative examples of DNA methylation alterations in certain diseases are shown. Diseases are marked by arrow heads (cancer, orange; Alzheimer's disease, yellow; etc.) and the type of DNA methylation change is indicated by a red (hypermethylation) or green (hypomethylation) bar inside the chromosome. In cancer cells (orange arrow heads), there are more than 100 genes documented in which CpG island promoter hypermethylation is associated with transcriptional inactivation. The SnapShot also indicates DNA methylation changes associated with genetic disorders such as α-thalassemia X-linked mental retardation syndrome (ATRX), facioscapulohumeral muscular dystrophy (FSHD), and immunodeficiency-centromere instability-facial anomalies (ICF). Initial data about DNA methylation changes in cardiovascular, neurological, and autoimmune disorders is emerging (indicated by different colored arrow heads). Traditionally, mapping DNA methylation patterns has relied on candidate gene approaches. The availability of large-scale epigenomic technologies, such as ChIP-on-chip, methyl-DIP-on-chip, ultradeep bisulfite sequencing, and the use of DNA demethylating agents associated with expression microarrays, are changing our view of the DNA methylome.
